Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue sup3: Omalizumab treatment in patients with severe chronic spontaneus urticaria: considerations from real-life experiences
Submit an article Journal homepage
808
Views
0
CrossRef citations to date
0
Altmetric
Omalizumab treatment in patients with severe chronic spontaneous urticaria: consideration on efficacy from real-life experiences

Omalizumab treatment in patients with severe chronic spontaneous urticaria: consideration from real-life experience in Italy

Riccardo AseroAmbulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Milan, Italy
Pages 1-2 | Published online: 03 Jan 2019

References

  • Zuberbier T, Aberer W, Asero R. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73:1393–1414.
  • Kaplan AP. Chronic Spontaneous Urticaria: pathogenesis and treatment considerations. Allergy Asthma Immunol Res. 2017;9:477–482.
  • Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569–573.
  • Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474–481.
  • Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–935.
  • Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–109.
  • Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67–75.
  • Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients. Allergol Internat. 2018;67:85–89.
  • Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol. 2015;115:126–910.
  • Maurer M, Kaplan A, Rosén K, et al. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol. 2018;141:1138–1139.e7.
  • Syrigos N, Grapsa D, Syrigou E. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis. Eur Ann Allergy Clin Immunol. . 2017;49:286–287.
  • Straesser M, Oliver E, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6:1386–1388.e1.
  • Marzano A, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2018; Nov 19
  • Tharp M, Bernstein J, Kavati A, et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence. JAMA Dermatol. 2018; Nov 14

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.